663 related articles for article (PubMed ID: 24894818)
1. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.
Damiola F; Pertesi M; Oliver J; Le Calvez-Kelm F; Voegele C; Young EL; Robinot N; Forey N; Durand G; Vallée MP; Tao K; Roane TC; Williams GJ; Hopper JL; Southey MC; Andrulis IL; John EM; Goldgar DE; Lesueur F; Tavtigian SV
Breast Cancer Res; 2014 Jun; 16(3):R58. PubMed ID: 24894818
[TBL] [Abstract][Full Text] [Related]
2. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex.
Hsu HM; Wang HC; Chen ST; Hsu GC; Shen CY; Yu JC
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2024-32. PubMed ID: 17932350
[TBL] [Abstract][Full Text] [Related]
5. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene.
Bartkova J; Tommiska J; Oplustilova L; Aaltonen K; Tamminen A; Heikkinen T; Mistrik M; Aittomäki K; Blomqvist C; Heikkilä P; Lukas J; Nevanlinna H; Bartek J
Mol Oncol; 2008 Dec; 2(4):296-316. PubMed ID: 19383352
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
7. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.
Le Calvez-Kelm F; Lesueur F; Damiola F; Vallée M; Voegele C; Babikyan D; Durand G; Forey N; McKay-Chopin S; Robinot N; Nguyen-Dumont T; Thomas A; Byrnes GB; ; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV
Breast Cancer Res; 2011 Jan; 13(1):R6. PubMed ID: 21244692
[TBL] [Abstract][Full Text] [Related]
8. Importance of Germline and Somatic Alterations in Human
Otahalova B; Volkova Z; Soukupova J; Kleiblova P; Janatova M; Vocka M; Macurek L; Kleibl Z
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982687
[TBL] [Abstract][Full Text] [Related]
9. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
10. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility.
Johnson N; Fletcher O; Palles C; Rudd M; Webb E; Sellick G; dos Santos Silva I; McCormack V; Gibson L; Fraser A; Leonard A; Gilham C; Tavtigian SV; Ashworth A; Houlston R; Peto J
Hum Mol Genet; 2007 May; 16(9):1051-7. PubMed ID: 17341484
[TBL] [Abstract][Full Text] [Related]
11. Cleavage of the BRCT tandem domains of nibrin by the 657del5 mutation affects the DNA damage response less than the Arg215Trp mutation.
Mendez G; Cilli D; Berardinelli F; Viganotti M; Ascenzi P; Tanzarella C; Antoccia A; di Masi A
IUBMB Life; 2012 Oct; 64(10):853-61. PubMed ID: 22941933
[TBL] [Abstract][Full Text] [Related]
12. Germline variants in MRE11/RAD50/NBN complex genes in childhood leukemia.
Mosor M; Ziółkowska-Suchanek I; Nowicka K; Dzikiewicz-Krawczyk A; Januszkiewicz-Lewandowska D; Nowak J
BMC Cancer; 2013 Oct; 13():457. PubMed ID: 24093751
[TBL] [Abstract][Full Text] [Related]
13. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer.
Tavtigian SV; Oefner PJ; Babikyan D; Hartmann A; Healey S; Le Calvez-Kelm F; Lesueur F; Byrnes GB; Chuang SC; Forey N; Feuchtinger C; Gioia L; Hall J; Hashibe M; Herte B; McKay-Chopin S; Thomas A; Vallée MP; Voegele C; Webb PM; Whiteman DC; ; ; ; Sangrajrang S; Hopper JL; Southey MC; Andrulis IL; John EM; Chenevix-Trench G
Am J Hum Genet; 2009 Oct; 85(4):427-46. PubMed ID: 19781682
[TBL] [Abstract][Full Text] [Related]
14. Protein-truncating variants in moderate-risk breast cancer susceptibility genes: a meta-analysis of high-risk case-control screening studies.
Aloraifi F; McCartan D; McDevitt T; Green AJ; Bracken A; Geraghty J
Cancer Genet; 2015 Sep; 208(9):455-63. PubMed ID: 26250988
[TBL] [Abstract][Full Text] [Related]
15. Ataxia telangiectasia-mutated (ATM) kinase activity is regulated by ATP-driven conformational changes in the Mre11/Rad50/Nbs1 (MRN) complex.
Lee JH; Mand MR; Deshpande RA; Kinoshita E; Yang SH; Wyman C; Paull TT
J Biol Chem; 2013 May; 288(18):12840-51. PubMed ID: 23525106
[TBL] [Abstract][Full Text] [Related]
16. Independent roles for nibrin and Mre11-Rad50 in the activation and function of Atm.
Cerosaletti K; Concannon P
J Biol Chem; 2004 Sep; 279(37):38813-9. PubMed ID: 15234984
[TBL] [Abstract][Full Text] [Related]
17. Growing recognition of the role for rare missense substitutions in breast cancer susceptibility.
Tavtigian SV; Chenevix-Trench G
Biomark Med; 2014; 8(4):589-603. PubMed ID: 24796624
[TBL] [Abstract][Full Text] [Related]
18. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
[TBL] [Abstract][Full Text] [Related]
19. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
Rebbeck TR; Mitra N; Domchek SM; Wan F; Chuai S; Friebel TM; Panossian S; Spurdle A; Chenevix-Trench G; ; Singer CF; Pfeiler G; Neuhausen SL; Lynch HT; Garber JE; Weitzel JN; Isaacs C; Couch F; Narod SA; Rubinstein WS; Tomlinson GE; Ganz PA; Olopade OI; Tung N; Blum JL; Greenberg R; Nathanson KL; Daly MB
Cancer Res; 2009 Jul; 69(14):5801-10. PubMed ID: 19584272
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families.
Coppa A; Nicolussi A; D'Inzeo S; Capalbo C; Belardinilli F; Colicchia V; Petroni M; Zani M; Ferraro S; Rinaldi C; Buffone A; Bartolazzi A; Screpanti I; Ottini L; Giannini G
Cancer Med; 2018 Jan; 7(1):46-55. PubMed ID: 29271107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
